US FDA Tech Modernization Plan’s Costs Uncertain
Executive Summary
Agency officials determining needs using existing budgets before requesting more funds and will engage with tech investors for design advice.
You may also be interested in...
BsUFA III Talks Could Move Cloud-Platform Goals Forward
US FDA wants to use biosimilars for a demonstration of cloud-based technology, an idea mentioned to increase the use of real-time review and enhance data analysis.
US FDA’s Data Strategy Under Increasing Pressure From Coronavirus Pandemic
As agency prepares to hear from stakeholders on its strategy, real-world data precedents already are being set thanks to COVID-19, Aetion tells the Pink Sheet.
Sign Of Normalcy? US FDA Schedules Meeting But Pauses Non-COVID Guidance Development
As the agency and country plot the steps to reopening, a full resumption of activities still seems a long way off.